Department of Neurology, University of Würzburg, Würzburg, Germany.
Department of Neurology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Pain. 2019 Oct;160(10):2316-2327. doi: 10.1097/j.pain.0000000000001623.
In this multicenter cross-sectional study, we determined sensory profiles of patients with (NL-1) and without neuropathic pain (NL-0) after nerve lesion and assessed immune-related systemic gene expression. Patients and matched healthy controls filled in questionnaires and underwent neurological examination, neurophysiological studies, quantitative sensory testing, and blood withdrawal. Neuropathic pain was present in 67/95 (71%) patients (NL-1). Tactile hyperalgesia was the most prominent clinical sign in NL-1 patients (P < 0.05). Questionnaires showed an association between neuropathic pain and the presence of depression, anxiety, and catastrophizing (P < 0.05 to P < 0.01). Neuropathic pain was frequently accompanied by other chronic pain (P < 0.05). Quantitative sensory testing showed ipsilateral signs of small and large fiber impairment compared to the respective contralateral side, with elevated thermal and mechanical detection thresholds (P < 0.001 to P < 0.05) and lowered pressure pain threshold (P < 0.05). Also, more loss of function was found in patients with NL-1 compared to NL-0. Pain intensity was associated with mechanical hyperalgesia (P < 0.05 to P < 0.01). However, quantitative sensory testing did not detect or predict neuropathic pain. Gene expression of peptidylglycine α-amidating monooxygenase was higher in NL patients compared with healthy controls (NL-1, P < 0.01; NL-0, P < 0.001). Also, gene expression of tumor necrosis factor-α was higher in NL-1 patients compared with NL-0 (P < 0.05), and interleukin-1ß was higher, but IL-10 was lower in NL-1 patients compared with healthy controls (P < 0.05 each). Our study reveals that nerve lesion presents with small and large nerve fiber dysfunction, which may contribute to the presence and intensity of neuropathic pain and which is associated with a systemic proinflammatory pattern.
在这项多中心横断面研究中,我们确定了神经损伤后伴有(NL-1)和不伴有神经病理性疼痛(NL-0)的患者的感觉特征,并评估了与免疫相关的全身基因表达。患者和匹配的健康对照者填写问卷并接受神经系统检查、神经生理学研究、定量感觉测试和血液采集。67/95(71%)名患者(NL-1)存在神经病理性疼痛。NL-1 患者最突出的临床体征是触觉超敏(P < 0.05)。问卷显示神经病理性疼痛与抑郁、焦虑和灾难化的存在之间存在关联(P < 0.05 至 P < 0.01)。神经病理性疼痛常伴有其他慢性疼痛(P < 0.05)。与相应的对侧相比,定量感觉测试显示同侧小纤维和大纤维损伤的迹象,表现为热觉和机械觉检测阈值升高(P < 0.001 至 P < 0.05)和压力疼痛阈值降低(P < 0.05)。此外,NL-1 患者的功能丧失比 NL-0 患者更严重。疼痛强度与机械性超敏相关(P < 0.05 至 P < 0.01)。然而,定量感觉测试并未检测或预测神经病理性疼痛。与健康对照组相比,NL 患者的肽基甘氨酸 α-酰胺化单加氧酶基因表达较高(NL-1,P < 0.01;NL-0,P < 0.001)。此外,NL-1 患者的肿瘤坏死因子-α基因表达高于 NL-0 患者(P < 0.05),而白细胞介素-1β 高于健康对照组(P < 0.05),白细胞介素-10 低于健康对照组(P < 0.05)。我们的研究表明,神经损伤表现为小纤维和大纤维功能障碍,这可能导致神经病理性疼痛的存在和强度,并与全身促炎模式相关。